Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials
Fezolinetant effectively reduces VMS in postmenopausal women at both 4 and 12 weeks, aligning with previous research. It also improves quality of life, with a promising safety profile. Given fezolinetant's potential for liver enzyme elevations, it is essential to monitor liver function at baseline and regularly thereafter (monthly for the first 3 months and at 6 and 9 months) to ensure patient safety. Further studies with larger sample sizes are needed to confirm these findings.
Authors
- Ahmed Abdelaziz (ORCID: https://orcid.org/0000-0002-1257-3450)
- Mohamed Abuelazm (ORCID: https://orcid.org/0000-0002-2514-0689)
- Basel Abdelazeem (ORCID: https://orcid.org/0000-0002-2919-6196)
- Majd M. AlBarakat (ORCID: https://orcid.org/0000-0002-4676-8942)
- Amr Elrosasy (ORCID: https://orcid.org/0000-0002-5592-3908)
- Rana B Altawalbeh (ORCID: https://orcid.org/0000-0003-0928-0873)
- Jehad Feras AlSamhori
- Rana Ahmed Youssef (ORCID: https://orcid.org/0009-0006-8973-7659)
- Mohamad A. Elzeftawy
Institutions
- University of Jordan (JO)
- West Virginia University (US)
- Cairo University (EG)
- Jordan University of Science and Technology (JO)
- Tanta University (EG)
- Al-Azhar University (ID)
- Alexandria University (EG)
Publication Details
- Journal
- Baylor University Medical Center Proceedings
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1080/08998280.2025.2491894
- Citations
- 1
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.29